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Abstract
The development of useful therapy for intraabdominal carcinomatosis originating from gas-
trointestinal cancer is an important theme in cancer therapy. We developed recently an experi-
mental model of intraabdominal carcinomatosis in nude mice by intraperitoneal transplantation of
human colon cancer cells (RPMI 4788). Using this model, we investigated the antitumor effects
of recombinant human interferon (rIFN)-beta and rIFN-gamma administered singly or in combi-
nation. Treatment was initiated 2 days after CD-1 nude mice were inoculated intraperitoneally
with 5 X 10(6) RPMI 4788 cells. Intraperitoneal administration for 10 consecutive days of either
rIFN-beta (2.5 X 10(5) IU/mouse/day) or rIFN-gamma (2.5 X 10(5) JRU/mouse/day) resulted in
a significant prolongation of survival compared with the saline control group [survival in the con-
trol: 41.8 +/- 5.6 days (mean +/- SD)]. Combined administration of rIFN-beta and rIFN-gamma for
10 days yielded a marked synergistic effect on the prolongation of survival (114.0 +/- 8.2 days).
However, combined administration of rIFN-beta and rIFN-gamma in a single dose equal to the
total dose given fractionally over 10 days did not yield a synergistic effect. These results suggest
that daily administration of rIFN-beta and rIFN-gamma combined may provide a highly potent
antitumor effect against human peritoneal carcinomatosis.
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